Literature DB >> 11097055

The interaction of drugs with DNA gyrase: a model for the molecular basis of quinolone action.

J G Heddle1, F M Barnard, L M Wentzell, A Maxwell.   

Abstract

DNA gyrase supercoils DNA in bacteria. The fact that it is essential in all bacteria and absent from eukaryotes makes it an ideal drug target. We discuss the action of coumarin and quinolone drugs on gyrase. In the case of coumarins, the drugs are known to be competitive inhibitors of the gyrase ATPase reaction. From a combination of structural and biochemical studies, the molecular details of the gyrase-coumarin complex are well established. In the case of quinolones, the drugs are thought to act by stabilising a cleavage complex between gyrase and DNA that arrests polymerases in vivo. The exact nature of the gyrase-quinolone-DNA complex is not known; we propose a model for this complex based on structural and biochemical data.

Entities:  

Mesh：

Substances：

Year:  2000        PMID： 11097055     DOI： 10.1080/15257770008033048

Source DB:  PubMed          Journal:  Nucleosides Nucleotides Nucleic Acids        ISSN： 1525-7770            Impact factor:   1.381


  21 in total

Review 1.  DNA topoisomerases and their poisoning by anticancer and antibacterial drugs.

Authors:  Yves Pommier; Elisabetta Leo; HongLiang Zhang; Christophe Marchand
Journal:  Chem Biol       Date:  2010-05-28

2.  Global transcriptome analysis of the responses of a fluoroquinolone-resistant Streptococcus pneumoniae mutant and its parent to ciprofloxacin.

Authors:  Estelle Marrer; A Tatsuo Satoh; Margaret M Johnson; Laura J V Piddock; Malcolm G P Page
Journal:  Antimicrob Agents Chemother       Date:  2006-01       Impact factor: 5.191

Review 3.  Quinolone-mediated bacterial death.

Authors:  Karl Drlica; Muhammad Malik; Robert J Kerns; Xilin Zhao
Journal:  Antimicrob Agents Chemother       Date:  2007-08-27       Impact factor: 5.191

Review 4.  In front of and behind the replication fork: bacterial type IIA topoisomerases.

Authors:  Claudia Sissi; Manlio Palumbo
Journal:  Cell Mol Life Sci       Date:  2010-02-18       Impact factor: 9.261

5.  NBTI 5463 is a novel bacterial type II topoisomerase inhibitor with activity against gram-negative bacteria and in vivo efficacy.

Authors:  Thomas J Dougherty; Asha Nayar; Joseph V Newman; Sussie Hopkins; Gregory G Stone; Michele Johnstone; Adam B Shapiro; Mark Cronin; Folkert Reck; David E Ehmann
Journal:  Antimicrob Agents Chemother       Date:  2014-02-24       Impact factor: 5.191

6.  Interaction between DNA gyrase and quinolones: effects of alanine mutations at GyrA subunit residues Ser(83) and Asp(87).

Authors:  F M Barnard; A Maxwell
Journal:  Antimicrob Agents Chemother       Date:  2001-07       Impact factor: 5.191

7.  Fluoroquinolones stimulate the DNA cleavage activity of topoisomerase IV by promoting the binding of Mg(2+) to the second metal binding site.

Authors:  Lisa M Oppegard; Heidi A Schwanz; Tyrell R Towle; Robert J Kerns; Hiroshi Hiasa
Journal:  Biochim Biophys Acta       Date:  2015-12-23

8.  Targeting Mycobacterium tuberculosis topoisomerase I by small-molecule inhibitors.

Authors:  Adwait Anand Godbole; Wareed Ahmed; Rajeshwari Subray Bhat; Erin K Bradley; Sean Ekins; Valakunja Nagaraja
Journal:  Antimicrob Agents Chemother       Date:  2014-12-22       Impact factor: 5.191

9.  Mapping simocyclinone D8 interaction with DNA gyrase: evidence for a new binding site on GyrB.

Authors:  C Sissi; E Vazquez; A Chemello; L A Mitchenall; A Maxwell; M Palumbo
Journal:  Antimicrob Agents Chemother       Date:  2009-10-26       Impact factor: 5.191

10.  The pentapeptide repeat proteins MfpAMt and QnrB4 exhibit opposite effects on DNA gyrase catalytic reactions and on the ternary gyrase-DNA-quinolone complex.

Authors:  Audrey Mérens; Stéphanie Matrat; Alexandra Aubry; Christine Lascols; Vincent Jarlier; Claude-James Soussy; Jean-Didier Cavallo; Emmanuelle Cambau
Journal:  J Bacteriol       Date:  2008-12-05       Impact factor: 3.490
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.